Roland Landman, Pierre de Truchis, Lambert Assoumou, Sidonie Lambert, Jonathan Bellet, Karine Amat, Bénédicte Lefebvre, Clotilde Allavena, Christine Katlama, Yazdan Yazdanpanah, Jean-Michel Molina, Ventzislava Petrov-Sanchez, Séverine Gibowski, Jean C Alvarez, Jacques Leibowitch, Jacqueline Capeau, Soraya Fellahi, Martin Duracinsky, Laurence Morand-Joubert, Dominique Costagliola, Jean-Claude Alvarez, Pierre-Marie Girard
BACKGROUND: Intermittent (on 4 days per week) antiretroviral therapy (ART) for patients with HIV-1 might be more convenient, better tolerated, and cheaper than continuous treatment. We aimed to establish the efficacy and safety of a 4-days-on and 3-days-off (intermittent) maintenance regimen versus a standard 7 day (continuous) maintenance regimen. METHODS: In a randomised, open-label, multicentre, parallel, non-inferiority trial, we randomly assigned (1:1) adults with HIV-1 infection with a plasma viral load (pVL) of less than 50 copies per mL for more than 12 months and no drug-resistance mutations to either the intermittent regimen or their existing continuous maintenance regimen, with stratification according to third therapeutic agent (protease inhibitor, non-nucleoside reverse transcriptase inhibitor, or integrase-strand transfer inhibitor)...
February 2022: Lancet HIV